Krystal Biotech (KRYS) AI Stock Analysis

• Market Cap: $3.82B
• Dividend Yield: N/A
• Average Volume (3M): 383.69K
• Price to Earnings (P/E): 31.7
• Beta (1Y): 0.81
• Revenue Growth: 247.53%
• EPS Growth: 118.34%
• Country: US
• Employees: 275
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): 1.20
• Shares Outstanding: 28,898,680
• 10 Day Avg. Volume: 556,703
• 30 Day Avg. Volume: 383,687
• PEG Ratio: 0.85
• Price to Book (P/B): 5.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 44.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $203.43
• Price Target Upside: 60.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 72 Outperform
• Price Target: $147.00 ▲( 16.04% Upside)

Krystal Biotech's strong financial performance and positive earnings call are key strengths, supported by revenue growth and strategic expansions. However, technical analysis indicates a bearish trend, and the valuation appears high, presenting potential risks. The company's ability to manage these challenges and maintain growth will be crucial for future stock performance.

Positive Factors

Market Expansion

Vyjuvek's EU market is viewed as a meaningful contribution to the current valuation.

Pipeline Development

The addition of KB111 and KB112 provides further validation of the utility of the HSV-1 based platform beyond the already FDA and EMA approved VYJUVEK for B-VEC, and continues to bring a sustainable value-add for the company.

Regulatory Approval

The European Commission is anticipated to provide a final decision on the CHMP opinion and a straightforward approval is highly likely.

Negative Factors

Patient Compliance

Patient compliance for Vyjuvek was 83%, a decline from the previous quarter due to various factors like complete sustained wound closure and plan switching.

Reimbursement Issues

The biggest update was the slowdown in reimbursement approvals which the company noted was related to the lower number of start forms received.

Revenue Challenges

Krystal (KRYS) shares fell -12.2% after announcing 1Q results which saw a significant decrease in Vyjuvek revenue despite maintaining relatively steady trends in compliance, lives covered, and gross margins.

Krystal Biotech Business Overview & Revenue Model

Company Description

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

How the Company Makes Money

Krystal Biotech primarily generates revenue through the development and commercialization of its gene therapy products. The company earns money by obtaining regulatory approvals and launching its therapies into the market, particularly targeting rare dermatological conditions. Key revenue streams include direct sales of approved therapies, licensing agreements, and potential milestone and royalty payments from partnerships. Additionally, Krystal Biotech may engage in collaborations with other pharmaceutical companies, contributing to its earnings through research and development funding, as well as shared profits from co-developed products.

Krystal Biotech Financial Statement Overview

Summary

Krystal Biotech exhibits strong financial health with significant revenue growth and robust profit margins. The balance sheet shows low leverage and efficient capital management, while cash flow generation has improved, enhancing financial flexibility.

Income Statement

Krystal Biotech has shown impressive financial performance with a significant increase in total revenue from $50.7 million in 2023 to $290.5 million in 2024, indicating a strong revenue growth rate. The gross profit margin is robust at 93.1% for 2024, and the net profit margin stands at 30.7%, reflecting high profitability. Despite earlier losses, the company has turned profitable, with both EBIT and EBITDA margins improving significantly.

Balance Sheet

The balance sheet shows a solid equity position with a debt-to-equity ratio of 0.008, indicating low leverage risk. The return on equity is 9.4%, reflecting efficient use of equity to generate profits. The equity ratio is high at 89.6%, suggesting a strong capital structure with a majority of assets financed by equity.

Cash Flow

The cash flow analysis reveals a positive turnaround with a free cash flow of $119.2 million in 2024 compared to negative figures in previous years. The operating cash flow to net income ratio is 1.38, indicating effective cash generation relative to net income. The company has managed to sustain positive cash flow, enhancing its financial flexibility.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
290.51M	50.70M	0.00	0.00	0.00
	Gross Profit
270.45M	47.60M	-4.05M	-2.77M	-1.85M
	EBIT
65.69M	-109.73M	-145.20M	-68.28M	-33.00M
	EBITDA
109.91M	17.90M	-145.20M	-65.31M	-30.32M
	Net Income Common Stockholders
89.16M	10.93M	-139.97M	-69.57M	-32.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
597.52M	532.18M	379.17M	438.10M	271.26M
	Total Assets
1.06B	818.36M	558.45M	626.29M	310.84M
	Total Debt
7.26M	8.09M	8.93M	8.02M	11.55M
	Net Debt
-337.60M	-350.23M	-152.97M	-333.22M	-256.72M
	Total Liabilities
109.46M	39.71M	36.22M	32.72M	18.76M
	Stockholders Equity
946.38M	778.64M	522.23M	593.58M	292.08M
Cash Flow		Free Cash Flow
119.18M	-100.60M	-153.55M	-116.27M	-40.93M
	Operating Cash Flow
123.42M	-88.80M	-100.57M	-47.94M	-26.08M
	Investing Cash Flow
-163.44M	82.64M	-114.08M	-226.77M	-11.18M
	Financing Cash Flow
27.01M	202.75M	35.35M	347.69M	118.02M

Krystal Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 126.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRYS, the sentiment is Negative. The current price of 126.68 is below the 20-day moving average (MA) of 147.20, below the 50-day MA of 164.63, and below the 200-day MA of 173.19, indicating a bearish trend. The MACD of -10.74 indicates Positive momentum. The RSI at 27.96 is Positive, neither overbought nor oversold. The STOCH value of 24.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRYS.

Krystal Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	72 Outperform	$3.82B	31.68	13.90%	―	247.53%	118.34%
VRNA	68 Neutral	$6.36B	―	-72.73%	―	―	-157.53%
SRPT	54 Neutral	$3.93B	19.61	-23.61%	―	59.15%	-1881.09%
AXSM	53 Neutral	$5.33B	―	-282.16%	―	72.16%	9.65%
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%
BPMC	48 Neutral	$6.54B	―	-47.71%	―	99.19%	48.43%
CYTK	36 Underperform	$3.90B	―	435.49%	―	412.21%	1.75%

Krystal Biotech Corporate Events

Krystal Biotech Holds Annual Stockholders Meeting

On May 16, 2025, Krystal Biotech held its Annual Meeting of Stockholders where key decisions were made, including the election of Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm for 2025. Additionally, stockholders approved the compensation of the company’s named executive officers for the fiscal year 2024, reflecting confidence in the company’s leadership and strategic direction.

The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.

Krystal Biotech Expands Gene Therapy Platform

On May 9, 2025, Krystal Biotech presented a poster at the Society for Investigative Dermatology Annual Meeting, detailing the expansion of its HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases. The studies demonstrated that the company’s gene therapy vectors, KB111 and KB112, can effectively transduce keratinocytes and express ATPases with minimal toxicity, indicating promising potential for treating these rare skin conditions.

The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.

Krystal Biotech Presents Promising Gene Therapy at ARVO

On May 5, 2025, Krystal Biotech presented research at the ARVO Annual Meeting showcasing their HSV-1-based gene therapy vector, KB801, which demonstrated sustained nerve growth factor expression in wounded murine corneas. This development highlights KB801’s potential as a safe and effective topical treatment for neurotrophic keratitis, offering a less burdensome alternative to the current treatment, cenegermin-bkbj, which requires frequent dosing.

Krystal Biotech Gains EU Approval for VYJUVEK®

On April 23, 2025, the European Commission approved VYJUVEK® for treating dystrophic epidermolysis bullosa (DEB) in Europe, marking it as the first corrective medicine for DEB in the region. This approval allows flexible dosing at home or in healthcare settings and is expected to significantly impact Krystal Biotech‘s market presence in Europe, with plans for a launch in Germany by mid-2025.